Learn the basics, understand the benefits, and build from there
Among 169,649 patients with MASLD, GLP-1 receptor agonist initiation was linked to significantly lower probability of incident cirrhosis [adjusted hazard ratio (aHR): 0.86, 95%CI: 0.80-0.93], hepatic decompensation (aHR: 0.77, 95%CI: 0.65-0.90), and hepatocellular carcinoma (HCC) (aHR: 0.79, 95%CI: 0.68-0.92) over a median follow-up of 3.5 years compared to non-users
As of 2025, retatrutide remains under investigation and has not yet received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA)
Now, I can have a piece of pizza and be full, as opposed to eating two and a half pieces, Erica says
Glucagon-like peptide-1 receptor agonists (or GLP-1, for short) work by mimicking a hormone in the body called glucagon-like peptide 1
Its caused by a combination of age, genetics, and hormones